Dr. Sherman received his medical degree from the Rosalind Franklin University/Chicago Medical School. He completed both an internship and residency in internal medicine at the Northwestern University McGaw Medical Center, where he also served as a chief medical resident. In addition, Dr. Sherman completed fellowship training at the University of California, San Francisco (UCSF) and also served as a research associate at the Howard Hughes Medical Institute at UCSF. Dr. Sherman is currently a Board Member of the Drug Information Association (DIA) and will be chairing the DIA 2008 Annual Meeting.
About IDM Pharma
IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.
For more information about the company and its products, visit http://www.idm-pharma.com.
This press release includes forward-looking statements that reflect
management's current views of future events including statements regarding
the Company's plans to collect, analyze and submit additional Phase 3 data
in an amended NDA for L-MTP-PE and to respond to other matters raised by
ODAC and the FDA, the Company's confidence that the proposed NDA amendment
will provide substantial evidence for the continued regulatory approval
|SOURCE IDM Pharma, Inc.|
Copyright©2007 PR Newswire.
All rights reserved